IL245317A0 - Ferric citrate for reducing cardiac failure in chronic kidney disease patients - Google Patents

Ferric citrate for reducing cardiac failure in chronic kidney disease patients

Info

Publication number
IL245317A0
IL245317A0 IL245317A IL24531716A IL245317A0 IL 245317 A0 IL245317 A0 IL 245317A0 IL 245317 A IL245317 A IL 245317A IL 24531716 A IL24531716 A IL 24531716A IL 245317 A0 IL245317 A0 IL 245317A0
Authority
IL
Israel
Prior art keywords
patients
heart failure
kidney disease
chronic kidney
ferric citrate
Prior art date
Application number
IL245317A
Other languages
English (en)
Hebrew (he)
Original Assignee
Keryx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keryx Biopharmaceuticals Inc filed Critical Keryx Biopharmaceuticals Inc
Publication of IL245317A0 publication Critical patent/IL245317A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IL245317A 2013-11-04 2016-04-27 Ferric citrate for reducing cardiac failure in chronic kidney disease patients IL245317A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361899866P 2013-11-04 2013-11-04
PCT/US2014/063643 WO2015066593A1 (en) 2013-11-04 2014-11-03 Ferric citrate for reducing cardiac failure in chronic kidney disease patients

Publications (1)

Publication Number Publication Date
IL245317A0 true IL245317A0 (en) 2016-06-30

Family

ID=53005244

Family Applications (1)

Application Number Title Priority Date Filing Date
IL245317A IL245317A0 (en) 2013-11-04 2016-04-27 Ferric citrate for reducing cardiac failure in chronic kidney disease patients

Country Status (15)

Country Link
US (3) US20160256486A1 (enExample)
EP (2) EP3065734A4 (enExample)
JP (3) JP2016535780A (enExample)
KR (1) KR102392441B1 (enExample)
CN (1) CN105873583A (enExample)
AU (1) AU2014341975A1 (enExample)
BR (1) BR112016009901A8 (enExample)
CA (1) CA2928200A1 (enExample)
EA (1) EA201690926A1 (enExample)
HK (1) HK1223031A1 (enExample)
IL (1) IL245317A0 (enExample)
MX (1) MX2016005734A (enExample)
SG (1) SG11201603091QA (enExample)
TW (2) TWI744215B (enExample)
WO (1) WO2015066593A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2768656C (en) 2009-07-21 2016-10-04 Keryx Biopharmaceuticals, Inc. Ferric citrate dosage forms
LT3003327T (lt) 2013-06-05 2017-12-27 Tricida Inc. Protonus surišantys polimerai, skirti geriamajam vartojimui
WO2015198304A1 (en) 2014-06-22 2015-12-30 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
CN113855703B (zh) 2014-12-10 2025-11-25 特里赛达公司 用于口服施用的质子结合聚合物
WO2017193024A1 (en) 2016-05-06 2017-11-09 Tricida, Inc. Hcl-binding compositions for and method of treating acid-base disorders
AU2018360867B2 (en) 2017-11-03 2024-12-12 Tricida, Inc. Compositions for and method of treating acid-base disorders
CN113613662A (zh) 2018-10-29 2021-11-05 法码科思莫斯控股有限公司 用羧基麦芽糖铁治疗铁缺乏
EA202191858A1 (ru) * 2019-06-12 2021-11-12 Фармакосмос Холдинг А/С Лечение дефицита железа у субъектов с риском нежелательных явлений со стороны сердечно-сосудистой системы и железо для лечения фибрилляции предсердий
WO2022251563A1 (en) * 2021-05-27 2022-12-01 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE351366B (enExample) * 1965-06-08 1972-11-27 Teikoku Hormone Mfg Co Ltd
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
US8093423B2 (en) * 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
MY162727A (en) 2005-08-18 2017-07-14 Panion & Bf Biotech Inc Pharmaceutical-grade ferric organic compounds, uses thereof, and methods of making the same
CN101374416A (zh) * 2006-01-30 2009-02-25 环亚有限公司 逆转、防止、延迟或稳定软组织钙化的方法
KR20080094013A (ko) * 2006-01-30 2008-10-22 글로보아시아 엘엘씨 연조직의 석회화 역전, 예방, 지연 또는 안정화 방법
CA2768656C (en) 2009-07-21 2016-10-04 Keryx Biopharmaceuticals, Inc. Ferric citrate dosage forms
JP5827326B2 (ja) * 2010-07-07 2015-12-02 アーデリクス,インコーポレーテッド リン酸輸送を阻害する化合物及び方法
EA201590062A1 (ru) * 2012-06-21 2016-02-29 Керикс Байофармасьютикалз, Инк. Применение лимонно-кислого железа при лечении пациентов с хронической почечной недостаточностью

Also Published As

Publication number Publication date
CN105873583A (zh) 2016-08-17
TWI744215B (zh) 2021-11-01
AU2014341975A1 (en) 2016-05-19
TW201609088A (zh) 2016-03-16
TW202203910A (zh) 2022-02-01
EP3065734A1 (en) 2016-09-14
BR112016009901A8 (pt) 2020-04-14
SG11201603091QA (en) 2016-05-30
KR102392441B1 (ko) 2022-05-02
HK1223031A1 (zh) 2017-07-21
JP2016535780A (ja) 2016-11-17
WO2015066593A1 (en) 2015-05-07
JP6828100B2 (ja) 2021-02-10
EP3747432A1 (en) 2020-12-09
US20250360167A1 (en) 2025-11-27
JP2019206562A (ja) 2019-12-05
EP3065734A4 (en) 2017-05-17
EA201690926A1 (ru) 2016-09-30
US20190307791A1 (en) 2019-10-10
CA2928200A1 (en) 2015-05-07
US20160256486A1 (en) 2016-09-08
MX2016005734A (es) 2016-11-08
KR20160096597A (ko) 2016-08-16
JP2021073230A (ja) 2021-05-13

Similar Documents

Publication Publication Date Title
CY2023027I1 (el) Ενωσεις πυριμιδινοδιονης εναντι καρδιακων παθησεων
FR25C1043I1 (fr) Utilisation de citrate ferrique dans le traitement de patients atteints d'une maladie rénale chronique
EP3862044C0 (en) TWO-TIP HEMODIALYSIS CATHETER
SG11201603091QA (en) Ferric citrate for reducing cardiac failure in chronic kidney disease patients
DK4023282T3 (da) Intravaskulær blodpumpe
EP3362123A4 (en) MEDICAL LUER CONNECTION
BR302013004536S1 (pt) Configuração aplicada em curativo médico
EP2869866A4 (en) Catheter pump
EP2968894A4 (en) MEDICAL CONNECTOR
DK3127563T3 (da) Pumpe, især blodpumpe
BR302013004565S1 (pt) Configuração aplicada em curativo médico
EP3821931C0 (en) ORONASAL PATIENT INTERFACE
EP2922514A4 (en) BI-RADIAL PATIENT INTERFACE
BR302013006823S1 (pt) Configuração aplicada em curativo médico
BR302013006043S1 (pt) Configuração aplicada a uma cadeira
EP2913047A4 (en) Pulmonary disease-specific therapeutic agent
EP2974614A4 (en) MIDSOLE WITH A LAYER STRUCTURE
HRP20190122T1 (hr) Protutijelo protiv adrenomedulina (adm) ili fragment protutijela protiv adm ili okosnica ne-ig protiv adm, namijenjeni reguliranju ravnoteže tekućina kod pacijenta s kroničnom ili akutnom bolešću
EP2914112A4 (en) TREATMENT OF CANCER WITH POMALIDOMIDE ON A PERSON WITH AFFECTED KIDNEY FUNCTION
BR302012004766S1 (pt) Configuracao aplicada em injetor médico
IL235547A0 (en) Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients
LT2958624T (lt) Transplantuotų pacientų transplantanto prieš šeiminiką ligos gydymas
JP2015535291A5 (enExample)
HRP20181142T1 (hr) Pripravak za smanjenje apsorpcije masti iz prehrane
CL2016000447A1 (es) Marcadores de riesgo para cardiovasculopatías en pacientes con nefropatía crónica.